Every retatrutide trial so far used once-weekly dosing, so the safety and effectiveness of any split schedule come from pharmacokinetic modelling and self-reported community experience, not trial data
This has given rise to two major phenomena in the aesthetic world: "Ozempic Face" and "Ozempic Body." Diet, exercise, and skin-tightening creams cannot reverse this
Pharmaceutical economics suggest Retatrutide will command premium pricing initially, potentially higher than Tirzepatide
A peptide triple agonist formulated both as a once-daily oral tablet and a once-monthly subcutaneous injection
Alternative administration routes like intranasal delivery are being explored in some research contexts, though subcutaneous injection remains the standard based on clinical trial protocols
Regular monitoring and adjusting the dosage may be required for individuals with these conditions